An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to
      rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal
      injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be
      evaluated.

A Study in Subjects With Retinitis Pigmentosa

Retinitis Pigmentosa

ADX-2191

An Open-label, Phase II Study of ADX-2191 in Subjects With Retinitis Pigmentosa

Assessing the safety of ADX-2191 in patients with retinitis pigmentosa from AE collection

Assessing the change in visual acuity in patients with retinitis pigmentosa treated with ADX-2191 using the Early Treatment Diabetic Retinopathy (ETDRS) chart.

Assessing the central retinal sensitivity in patients using microperimetry, measured in decibels

Assessing the change in dark-adapted retinal sensitivity in patients using dark adapted chromatic perimetry, measured in decibels

Assessing the change in central subfield foveal thickness and ellipsoid zone area/width in patients using Spectral-Domain Optical Coherence Tomography (SD-OCT) as measured in square millimeters

A Study in Subjects With Retinitis Pigmentosa

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status